We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
GLP-1 Weight Care
Understand GLP-1 medicines, their benefits and risks, and request an evaluation through our clinical partner. Treatment is available only when a licensed provider determines it is medically appropriate.
Licensed-provider evaluation required · Prescription not guaranteed
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team · Kevin Wolfe, Founder & CEO
Kindr Health Inc. organizational NPI 1609792902 · Last reviewed: July 3, 2026
What it is
GLP-1 receptor agonists — semaglutide and tirzepatide — are a class of medications originally developed for type 2 diabetes that produce significant, sustained weight loss by regulating the appetite and metabolic systems. They are now the most clinically effective pharmacologic treatment for obesity and metabolic dysfunction.
Compounded semaglutide is available through our clinical partner when a licensed provider determines it is medically appropriate. Medication is prepared and dispensed by our licensed compounding pharmacy.
The science
When estrogen declines during menopause, the body's metabolic function changes fundamentally. Fat redistributes from the hips and thighs — where estrogen directed it — to the abdomen. Insulin sensitivity decreases. The appetite-regulating hormones leptin and ghrelin shift. Resting metabolic rate drops.
This is not weight gain from eating more or moving less. It is the direct result of hormonal change. And it will not respond the way weight gain in your 30s did — no matter how disciplined you are.
GLP-1 receptor agonists regulate appetite signaling and glucose-dependent insulin release. Some patients may use GLP-1 treatment and HRT together, but each requires an individual risk-benefit assessment; neither treatment guarantees a particular outcome.
GLP-1 medicines explained
The active ingredient in the FDA-approved medicines Ozempic and Wegovy. Given as a weekly injection, usually started at a low dose and increased slowly to reduce side effects. Compounded versions are not FDA-approved, and the FDA limits when they can be made.
Dual GIP/GLP-1 receptor agonist — the active ingredient in the FDA-approved medicines Mounjaro and Zepbound. Weekly injection. Stronger metabolic and appetite effects in clinical trials than semaglutide alone for many patients.
Some people use both. Whether either treatment is appropriate depends on an individual clinical review by a licensed healthcare professional.
Eligibility
Your provider determines eligibility following clinical review. GLP-1 is generally appropriate for:
Eligibility determined by your provider at intake. Not all patients will qualify.
Who it's for
What to expect
Your provider reviews your weight history, metabolic markers, personal and family medical history, and current medications.
Treatment starts at a low dose to minimize gastrointestinal side effects. Your protocol is built around your tolerance and response.
When prescribed, medication is prepared and dispensed by our licensed compounding pharmacy.
Your provider titrates your dose monthly based on response, side effects, and weight outcomes — included in your plan.
FDA / Compounding Notice
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Results vary. All treatment decisions are made solely by licensed healthcare professionals.
Clinical evidence
Finding
Tirzepatide produced average weight reductions of 15–20.9% over 72 weeks in adults with obesity.
Source: SURMOUNT-1 Trial — New England Journal of Medicine, 2022
Finding
Semaglutide 2.4mg produced sustained weight loss of ~15% over 68 weeks in adults with overweight or obesity.
Source: STEP-1 Trial — New England Journal of Medicine, 2021
Finding
GLP-1 therapy improves insulin sensitivity and metabolic markers in midlife and postmenopausal women.
Finding
Combined hormone optimization and metabolic therapy in midlife women improves coordinated outcomes.
Source: Menopause: The Journal of NAMS
Medically reviewed
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team · Kevin Wolfe, Founder & CEO
Kindr Health Inc. organizational NPI 1609792902 · Last reviewed: July 3, 2026
This page has been reviewed for clinical accuracy against current NAMS, ACOG, and NIH guidelines by a licensed clinician.
FAQ
No. Ozempic is an FDA-approved branded semaglutide product. Compounded semaglutide is prepared and dispensed by a licensed compounding pharmacy and is not an FDA-approved product or an equivalent substitute. Availability depends on current law and an individual clinical review.
In clinical trials, semaglutide produced average weight loss of approximately 15% of body weight over 68 weeks, and tirzepatide produced 15–20% over 72 weeks. Individual results vary widely depending on dose, adherence, baseline weight, and metabolic context. Coordinated HRT + GLP-1 outcomes in menopausal women often exceed GLP-1 monotherapy outcomes.
Appetite suppression usually appears within the first 1–2 weeks. Visible weight changes typically begin around weeks 4–8. Most patients reach their plateau between months 9 and 14. Your provider tracks your response monthly and adjusts your dose accordingly.
The most common side effects are nausea, decreased appetite, constipation or loose stools, and reflux — especially during the first weeks of treatment and after dose increases. Side effects are generally mild to moderate and improve with slow titration and dietary adjustments. Rare but serious risks include pancreatitis, gallbladder disease, and a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION)—sudden, painless vision loss in one eye that can include permanent vision loss. Contact a clinician right away if your vision changes suddenly. A licensed provider screens for contraindications and discusses risks before any prescription. This is educational information, not medical advice.
Some patients may use both, but a licensed healthcare professional must review your medicines, health history, contraindications, and goals before deciding whether either treatment is medically appropriate.
GLP-1 medications are subcutaneous self-injections — typically once weekly. The needle is very small (similar to insulin pens). Your starter kit includes detailed instructions, supplies, and access to provider messaging if you have questions during your first injections.
Studies show that most patients regain a portion of lost weight after discontinuing GLP-1 therapy. The medication does not "cure" obesity — it treats it. Many patients use GLP-1 long term; others taper down once they have established new habits and reached their weight goals. Your provider works with you on a long-term plan.
Availability depends on clinician licensure, pharmacy service area, current law, and your individual clinical review. The secure patient portal confirms the options available for your location.
Sources & references
Related services
Personalized compounded hormone therapy — estradiol, progesterone, testosterone, and more — prescribed by a licensed menopause clinician.
Read about Menopause HRT →
At-home hormone panel — reviewed by your provider in context of your symptoms, not just a number on a reference range.
Read about Hormone Lab Testing →
Specialized care for women in transition — starting as early as 35. Providers who don't dismiss you as too young.
Read about Perimenopause Care →
Personalized care, licensed clinicians, all 50 states.
Start nowkindr Health is a telehealth platform. Prescription medications require clinical evaluation and provider approval. Compounded medications are prepared by state-licensed, FDA-registered pharmacies and are not FDA-approved drug products. Individual results vary. Not an emergency service. For emergencies call 911. HIPAA Compliant · LegitScript Certification pending · Licensed in all 50 states.